Flulaval is commonly used in the prophylaxis of illness caused by the seasonal influenza viruses, including the circulating Influenza A subtype viruses and type B viruses contained in the annual formulation. Its clinical utility is associated with the supportive benefits it provides in preventing the disease and easing the impact of the infection.

This immunization is used to support the prevention of the severe, abrupt onset of the flu, which is characterized by the clustering of Systemic Illness and Febrile Symptoms and intense Musculoskeletal Discomfort. The therapeutic benefit may assist with reducing the risk of contracting the influenza illness, which may contribute to easing the disruption and functional strain on daily life during the flu season.

The use is relevant for individuals aged 6 months and older who seek prevention of seasonal influenza. The vaccine is considered relevant for individuals in Vulnerable and High-Risk Groups, which includes older adults, children, and individuals with chronic health conditions, and may be relevant for reducing the likelihood of developing severe complications like secondary pneumonia or severe febrile illnesses.

“The immunization is applied in contexts marked by temporary physiological imbalance and contributes to easing the overall symptom load.”

---

Quick Fact: Relief for Flu Symptoms

Flulaval may assist with decreasing the potential for flu-related hospitalization and supports lessening the severity of symptoms for those who still experience a breakthrough infection.

The eligibility for Flulaval Quadrivalent is strictly defined by regulatory labeling and is primarily determined by age and medical history, rather than therapeutic context. The vaccine is approved for use in persons aged 6 months and older; it is not approved for children younger than 6 months of age.

---

| Classification | Eligibility Status | | :--- | :--- | | Populations for whom use is contraindicated | Individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any vaccine component or following a previous dose of any influenza vaccine. | | Eligibility-Related Restrictions | A history of Guillain-Barré Syndrome (GBS) within six weeks of a prior influenza vaccination requires careful consideration of potential benefits and risks. | | Pregnancy and Lactation | Safety and effectiveness have not been established in pregnant women or nursing mothers (US FDA). |

---

Use in immunocompromised persons (including those on immunosuppressive therapy) may lead to a lower immune response compared to healthy individuals. The restrictions on use for individuals with specific conditions, such as severe hepatic or renal impairment, are not listed as absolute contraindications in the official prescribing information. The regulatory documentation clearly establishes the minimum age for use and the absolute contraindications that prohibit administration.

Flulaval Interactions with other medicines and products

The regulatory documentation for Flulaval (Inactivated Influenza Vaccine) emphasizes interactions that affect the immune response rather than traditional pharmacokinetic pathways. The official prescribing information documents a single primary class of interaction: a pharmacodynamic effect with Immunosuppressive Therapy.

---

Interaction Scope

Category	Official Regulatory Statement
Interacting Product Class	Immunosuppressive therapy (as a class of agents).
Mechanistic Basis	Pharmacodynamic (functional/immunological) interaction.
Outcome	Potential for a lower immune response compared to non-immunosuppressed individuals.
Timing Rules	None are documented requiring specific time separation from other medicines.

---

Interaction Classifications (High-Level)

Classification	Regulatory Statement Summary
Severity Context	Documented under a Warning or Precaution category regarding Altered Immunocompetence.
Restrictions	No specific drug-drug combinations are labeled as contraindicated due to interaction risk.

---

Resulting Interaction Structure

The interaction profile is defined by the risk of reduced efficacy in specific populations. If Flulaval is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the resulting immune response may be lower. The official documentation confirms the absence of documented metabolic (CYP- or transporter-mediated) interactions, food/alcohol interactions, or any mandatory timing separation requirements with other medicinal products.

How Flulaval Works

Flulaval is an inactivated, split-virion influenza vaccine that works by engaging the body's adaptive immune system to induce a specific immune response against targeted viral components. It introduces inactivated surface proteins, primarily hemagglutinin (HA) and neuraminidase (NA), which act as antigens.

These antigens stimulate B lymphocytes to undergo differentiation, initiating the primary humoral response and resulting in the production of strain-specific antibodies. The generated anti-HA antibodies mediate the neutralization of the influenza virus by inhibiting the process of attachment and fusion to host respiratory cells, thereby modulating viral interaction with host cells and subsequent replication. This pathway effect modulates the early molecular steps required for systemic viral proliferation.

Beyond immediate antibody production, the vaccine supports the formation of long-lived memory B cells and memory T cells. This establishes an immunological memory reserve. The physiological consequence is that upon future exposure to the live, circulating virus, the immune system is primed to mount a rapid and intensified (anamnestic) antibody response, which represents the key mechanistic function of immunological memory.

Administration Scope

The administration of Flulaval follows a protocol detailing the route, preparation, and dosing regimen. Flulaval is administered solely by intramuscular (IM) injection; other routes, such as intravenous or subcutaneous administration, are prohibited.

---

Labeled Dosing and Frequency

The standard dose volume is 0.5 mL for all approved individuals aged 6 months and older. Before administration, the vaccine suspension must be shaken well and visually inspected to ensure the liquid is free of particulate matter and discoloration.

Age Group	Dosing Schedule	Dosing Interval Constraint
Adults and Older Children (≥ 9 years)	Single 0.5 mL dose	Administered annually
Children (6 months through 8 years)	One or two 0.5 mL doses	Two doses, if required, must be given at least 4 weeks apart

For children 6 months through 8 years of age, the required dose frequency is determined by whether they have previously received an influenza vaccine. Those not previously vaccinated require the two-dose primary series.

---

Special Procedural Conditions

Administration requires specific attention to the injection site, which is age-dependent. The preferred site for infants aged 6 through 11 months is the anterolateral thigh muscle. For individuals 12 months and older, the deltoid muscle of the upper arm is the preferred site.

Additionally, proper product handling requires that any multi-dose vials used must be discarded 28 days after the container is first punctured.

Overview of Clinical Trials

Clinical research has investigated the safety and immunogenicity of Flulaval, an inactivated influenza virus vaccine. Trials have primarily focused on measuring the immune response (antibody production) against the influenza A and B strains contained in the vaccine for that season. The studies were conducted across various age groups, including children, adolescents, and adults.

---

Efficacy and Safety Data

Early clinical development included immunogenicity trials that compared Flulaval to other licensed influenza vaccines. These studies aimed to demonstrate that the immune response elicited by Flulaval was non-inferior to the comparator vaccines against the circulating influenza strains. The primary clinical endpoint in most efficacy studies for influenza vaccines is the prevention of laboratory-confirmed influenza illness.

• Children and Adolescents: A large-scale randomized clinical trial in children aged 3 to 8 years reported a vaccine efficacy of approximately 55% against confirmed influenza cases. Efficacy against moderate-to-severe illness was reported to be higher in this population.
• Adults: Studies evaluated Flulaval's immune response in adults 18 years of age and older. These trials noted that the immune response in older individuals (geriatric subjects) may be lower compared to younger subjects.

---

Safety Profile Observations

Across clinical trials, Flulaval demonstrated a safety profile comparable to other licensed inactivated influenza vaccines. The most frequently reported adverse reactions, solicited from subjects, were typically mild or moderate and localized.

Age Group	Most Common Local Reaction	Most Common Systemic Reactions (Examples)
Adults (18+)	Pain at injection site	Muscle aches, headache, fatigue
Children (3-17)	Pain at injection site	Headache, muscle aches, irritability

Common questions about Flulaval (FAQ)

Q: What are the ingredients in Flulaval?

A: The active ingredients in Flulaval are purified surface proteins, specifically hemagglutinin and neuraminidase, which come from the influenza virus strains selected for the current season. The official product information also states that the vaccine is manufactured without thimerosal. Because a history of a severe allergic reaction (anaphylaxis) to any component is a contraindication, the official documentation mentions that trace amounts of egg protein are components of the vaccine.

Q: Can a person with a history of Guillain-Barré Syndrome (GBS) get this vaccine?

A: Official regulatory information notes that if a person has experienced Guillain-Barré syndrome (GBS) within six weeks of a prior influenza vaccination, the decision to administer Flulaval requires careful consideration. This decision should be made by a healthcare provider who considers the potential benefits of the vaccine versus any potential risks associated with a history of GBS.

Q: What happens if the vaccine is accidentally frozen?

A: The official product instructions strictly state that Flulaval must not be frozen. If the vaccine has been subjected to freezing temperatures, it must be discarded. This is because freezing may compromise the vaccine's ability to stimulate an immune response, resulting in a loss of effectiveness.

Q: What is the exact name of the manufacturer of Flulaval?

A: Flulaval is manufactured by ID Biomedical Corporation of Quebec, which is a subsidiary of GlaxoSmithKline (GSK). This information is documented in the product's official regulatory documentation.

Q: Where is the correct injection site for a 5-year-old child?

A: According to the official administration instructions, the preferred site for intramuscular injection for individuals aged 12 months and older is the deltoid muscle. Therefore, for a 5-year-old child, the deltoid muscle in the upper arm is the standard site for administration.

Storage and Disposal of Flulaval

The storage of Flulaval (Influenza Vaccine) must strictly adhere to mandated cold chain requirements to maintain product stability. The vaccine must be kept under refrigeration between 2 C and 8 C (36 F and 46 F).

Required Storage Conditions

Condition	Requirement
Temperature	Do not freeze; discard if freezing occurs.
Light Protection	Store in the original package to protect from light.
Multi-dose Vial Limit	Discard multi-dose vials 28 days after the first puncture.

Disposal Instructions

Any unused product or waste material, including single-dose syringes, must be disposed of in accordance with local requirements for pharmaceutical waste. Products must not be used beyond the expiration date listed on the label.